Skip to main content
Premium Trial:

Request an Annual Quote

Gilead's Plan

Premium

Gilead Sciences wants to turn cancer into a condition that patients can manage with medication, even if they have to live with it for a long time, says CNN Money's Geoff Colvin. Colvin interviewed Gilead's CEO, John Martin, about his plans for Gilead and the company's plans to develop a new initiative to fight cancer. Gilead has just signed a new agreement with Yale to help identify molecular targets that could be inhibited in order to put cancer into remission, Martin says. "Just look at how, with HIV, we were able to come up with multiple products that we could use in combination to keep HIV basically in remission in a patient and let the patient live a normal life. With our chemistry and biological expertise, we envision doing a similar thing for cancer chemotherapy," he tells Colvin. Martin also says he wants to create medications that take into account real-world behavior of patients, and make it simple — not complicated — for patients to take their prescribed drugs.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.